Zacks Research Analysts Boost Earnings Estimates for CPRX

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) – Stock analysts at Zacks Research lifted their Q3 2026 earnings per share (EPS) estimates for shares of Catalyst Pharmaceuticals in a research note issued to investors on Wednesday, March 18th. Zacks Research analyst Team now expects that the biopharmaceutical company will post earnings per share of $0.64 for the quarter, up from their prior estimate of $0.59. Zacks Research has a “Strong-Buy” rating on the stock. The consensus estimate for Catalyst Pharmaceuticals’ current full-year earnings is $1.90 per share. Zacks Research also issued estimates for Catalyst Pharmaceuticals’ Q3 2027 earnings at $0.69 EPS and FY2028 earnings at $3.00 EPS.

CPRX has been the subject of several other research reports. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a research note on Monday, December 29th. Citigroup boosted their target price on Catalyst Pharmaceuticals from $33.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, March 3rd. Two investment analysts have rated the stock with a Strong Buy rating and three have assigned a Buy rating to the company’s stock. According to MarketBeat.com, Catalyst Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $34.00.

Catalyst Pharmaceuticals Trading Down 2.1%

NASDAQ:CPRX opened at $22.33 on Friday. The firm has a market capitalization of $2.73 billion, a price-to-earnings ratio of 13.21, a PEG ratio of 0.67 and a beta of 0.75. Catalyst Pharmaceuticals has a 1-year low of $19.05 and a 1-year high of $26.58. The business’s 50-day moving average price is $23.94 and its two-hundred day moving average price is $22.54.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in CPRX. Rockefeller Capital Management L.P. raised its position in Catalyst Pharmaceuticals by 29.4% during the fourth quarter. Rockefeller Capital Management L.P. now owns 29,680 shares of the biopharmaceutical company’s stock worth $693,000 after acquiring an additional 6,752 shares in the last quarter. Hsbc Holdings PLC lifted its stake in Catalyst Pharmaceuticals by 91.9% in the 4th quarter. Hsbc Holdings PLC now owns 57,929 shares of the biopharmaceutical company’s stock valued at $1,362,000 after purchasing an additional 27,739 shares during the last quarter. Invesco Ltd. grew its holdings in Catalyst Pharmaceuticals by 4.9% during the fourth quarter. Invesco Ltd. now owns 1,293,478 shares of the biopharmaceutical company’s stock worth $30,190,000 after purchasing an additional 60,221 shares during the period. EP Wealth Advisors LLC acquired a new position in Catalyst Pharmaceuticals during the fourth quarter worth approximately $630,000. Finally, Mackenzie Financial Corp bought a new stake in Catalyst Pharmaceuticals in the fourth quarter valued at approximately $210,000. Institutional investors own 79.22% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).